[go: up one dir, main page]

WO2001018549A8 - Therapies et reactifs augmentant la resistance au stress et la longevite - Google Patents

Therapies et reactifs augmentant la resistance au stress et la longevite

Info

Publication number
WO2001018549A8
WO2001018549A8 PCT/US2000/024487 US0024487W WO0118549A8 WO 2001018549 A8 WO2001018549 A8 WO 2001018549A8 US 0024487 W US0024487 W US 0024487W WO 0118549 A8 WO0118549 A8 WO 0118549A8
Authority
WO
WIPO (PCT)
Prior art keywords
daf
agents
methods
cytoprotective effects
identifying modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/024487
Other languages
English (en)
Other versions
WO2001018549A1 (fr
Inventor
Samuel T Henderson
Thomas E Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TorreyPines Therapeutics Inc
Original Assignee
TorreyPines Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TorreyPines Therapeutics Inc filed Critical TorreyPines Therapeutics Inc
Priority to AU73537/00A priority Critical patent/AU7353700A/en
Publication of WO2001018549A1 publication Critical patent/WO2001018549A1/fr
Publication of WO2001018549A8 publication Critical patent/WO2001018549A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés d'identification d'agents pouvant activer C. elegans DAF-16 ainsi que des homologues humains de celui-ci ou de leurs gènes correspondants, par lesquels des effets cytoprotecteurs dans des cellules pourraient être entraînés. Ces effets cytoprotecteurs peuvent aboutir à une résistance accrue au stress causé par l'environnement, une longévité rallongée et à une plus grande vigueur en fin de vie, sans inhibition importante des voies métaboliques marquant l'insuline. L'invention concerne également les agents thérapeutiques identifiés et les procédés de traitement employant ces agents.
PCT/US2000/024487 1999-09-07 2000-09-07 Therapies et reactifs augmentant la resistance au stress et la longevite Ceased WO2001018549A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73537/00A AU7353700A (en) 1999-09-07 2000-09-07 Therapies and reagents for increasing stress resistance and life span

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15282599P 1999-09-07 1999-09-07
US60/152,825 1999-09-07

Publications (2)

Publication Number Publication Date
WO2001018549A1 WO2001018549A1 (fr) 2001-03-15
WO2001018549A8 true WO2001018549A8 (fr) 2001-06-07

Family

ID=22544612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024487 Ceased WO2001018549A1 (fr) 1999-09-07 2000-09-07 Therapies et reactifs augmentant la resistance au stress et la longevite

Country Status (2)

Country Link
AU (1) AU7353700A (fr)
WO (1) WO2001018549A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1581624A4 (fr) * 2002-08-09 2007-01-24 Univ California Genes eukaryotes impliques dans la regulation de la duree de vie adulte
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US7932049B2 (en) * 2002-12-23 2011-04-26 University Of Massachusetts Methods of identifying longevity modulators and therapeutic methods of use thereof
US7858327B2 (en) * 2002-12-23 2010-12-28 University Of Massachusetts Methods of identifying longevity modulators and therapeutic methods of use thereof
DE10303850A1 (de) * 2003-01-30 2004-08-12 Aventis Pharma Deutschland Gmbh Screening-Assay auf Basis des Forkhead-Transkriptionsfaktor-abhängigen sod-3-Promotors zur Identifizierung von AKT modulierenden Verbindungen oder von stromaufwärts liegenden Regulatoren, wie etwa Insulin/IGF1-Rezeptoren
US7435868B2 (en) 2003-01-30 2008-10-14 Sanofi-Aventis Deutschland Gmbh Screening assay based on the forkhead transcription factor-dependent sod-3 promoter
JP2007503348A (ja) 2003-08-26 2007-02-22 オートリブ ディヴェロプメント アクチボラゲット ２つの引き締め装置を備えたベルトローラ
US20090280062A1 (en) * 2008-04-17 2009-11-12 Chi-Huey Wong Longevity-promoting effects of acetic acid and reishi polysaccharide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019092A4 (fr) * 1997-05-15 2004-12-15 Gen Hospital Corp Outils therapeutiques et diagnostiques pour desordres lies a une mauvaise tolerance glucidique

Also Published As

Publication number Publication date
WO2001018549A1 (fr) 2001-03-15
AU7353700A (en) 2001-04-10

Similar Documents

Publication Publication Date Title
WO2005003766A3 (fr) Procedes de regulation du metabolisme et de la fonction mitochondriale
ATE540129T1 (de) Target zur therapie kognitiver behinderungen
WO2003089457A3 (fr) Inhibiteurs peptidiques de la proteine kinase c$g(g) pour la gestion de la douleur
AU2003304386A8 (en) Methods for treating and preventing apoptosis-related diseases using rna interfering agents
AU2002232393A1 (en) Methods for identifying genes associated with diseases or specific phenotypes
NO20006604D0 (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
MX9708401A (es) Genes reguladores de la cromatina.
DE69828919D1 (de) Überprüfung des kathodischen Schutzes von erdverlegten Rohrleitungen
AU2003249645A8 (en) Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
EP1226257A4 (fr) Criblage et utilisation d'agents bloquant ou activant l'epissage d'inteines par des exteines naturelles ou homologues
WO2001018549A8 (fr) Therapies et reactifs augmentant la resistance au stress et la longevite
WO2001021771A3 (fr) Compositions et methodes d'inhibition de l'arret du cycle cellulaire g2 et de sensibilisation de cellules aux agents de degradation d'adn
IL137429A0 (en) Methods and compsitions for treating diseases and conditions of the eye
DK1083934T3 (da) Genterapifremgangsmåder
DE60044503D1 (de) Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie
NO961576D0 (no) Martensittisk stålledning og fremstilling av denne
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
WO2002027034A3 (fr) Procede d'identification de regions genetiques associees a une maladie et prevision de la reponse a des agents therapeutiques
WO2002061430A3 (fr) Techniques et reactifs destines au traitement des troubles auto-immuns
WO2002062205A3 (fr) Methodes de diagnostic et de traitement des cardiopathies
EP1414478A4 (fr) Inhibition de la neurodegenerescence
BR0314541A (pt) Tratamento de demência e doença de parkinson
ES2187180T3 (es) Genes que confieren un fenotipo obeso.
AU6012798A (en) Genetic methods for identifying individuals for improving well being and perf ormance through exercise

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP